Medtronic plans to acquire Scientia Vascular for $550M. Explore what the deal changes for stroke intervention devices and neurovascular procedure access.
Rapid Medical disclosed late-breaking results from its DISTALS randomized controlled trial showing that the TIGERTRIEVER 13 thrombectomy device achieved significantly higher tissue reperfusion without symptomatic intracranial hemorrhage compared with medical management in medium vessel occlusion stroke. The data were presented at the 2026 International Stroke Conference and form the basis for a planned United States
Vesalio has received 510(k) clearance from the U.S. Food and Drug Administration for enVast, its stent-based coronary clot retrieval system, making it the first device of its kind approved for mechanical thrombectomy in the cardiac circulation. The approval authorizes enVast for U.S. commercialization, following prior regulatory clearance and use in European markets. The device is